Skip to main content
. 2017 Oct 27;103(1):51–60. doi: 10.3324/haematol.2017.174672

Figure 1.

Figure 1.

Treatment at registration vs. age. Patients in various age groups were treated at registration with anagrelide, hydroxycarbamide, interferon, combination therapy or other monotherapy. *Includes busulfan, interferon, pipobroman, P32, thromboreductin (anagrelide).